Medincell Stock Rises Nearly 3% and Leads the Pack in the SBF 120
The biotech company from Montpellier advances in mid-morning trading, bucking the trend of a Parisian market weighed down by inflationary fears linked to the oil shock. The stock confirms its medium-term momentum.
A 2.61% Increase Elevates the Stock Among the Top Gainers of the SBF 120
Medincell gains 2.61% to €27.54 in mid-morning trading, while the SBF 120 drops by 0.67% and the CAC 40 declines by 0.70%. The movement extends the upward trend documented last week, following a 2% increase observed on Friday. Over three months, the performance is close to 29%, and reaches nearly 71% over one year, showing a trajectory significantly disconnected from the broader index. Today's rise places the share price above the MM20 (€27.17, a gap of +1.4%), while the stock maintains a comfortable cushion relative to its longer averages, about 9.6% above the MM50 and 8.1% above the MM200.
Short Position Accumulated to 2.55% of Capital, Up by 1.09 Points Over a Month
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Four funds now cumulatively hold 2.55% of the capital in short positions, according to reviewed declarations, up from 1.46% thirty days ago. The increase reaches 1.09 points in a month, a notable rise even though the cumulative total remains modest relative to the float. This implies that some institutional investors are reinforcing a position contrary to the stock's bullish movement, either betting on a consolidation after the rally or to hedge an existing exposure. The figure is worth monitoring but should not be overinterpreted: it remains far from the stress levels observed on other SBF 120 stocks. Technically, the RSI at 53 remains neutral and does not send an extreme signal. The resistance of €28.72, already tested at the end of May and then on June 2 according to recent briefs, becomes the immediate graphical reference, less than 5% from the current price.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.